Barrington Research Upgrades Anika Therapeutics to Outperform, Announces $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has upgraded Anika Therapeutics (NASDAQ:ANIK) from Market Perform to Outperform and set a price target of $24.
August 14, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anika Therapeutics has been upgraded to Outperform by Barrington Research, with a new price target of $24.
The upgrade from Market Perform to Outperform by Barrington Research indicates a positive outlook for Anika Therapeutics. The new price target of $24 suggests potential upside for the stock. This could lead to increased investor interest and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100